Pathologie du sein; Traitement hormonal; Observance thérapeutique; Longue durée; Cancer du sein; Long terme; Médicament; Tumeur maligne; Chimiothérapie; Traitement adjuvant; Glande mammaire; Cancer; Traitement; Pathologie de la glande mammaire; Breast disease; Hormone therapy; Treatment compliance; Long lasting; Breast cancer; Long term; Drug; Malignant tumor; Chemotherapy; Adjuvant treatment; Mammary gland; Treatment; Mammary gland diseases
Résumé :
[fr] L'objectif de l'hormonothérapie adjuvante dans le cancer du sein est d'atteindre en pratique quotidiennee, une efficacité comparable à celle obtenue au cours des études cliniques. Malgré l'efficacité démontrée de l'hormonothérapie, la compliance constitue un défi majeur et un problème multidimensionnel. Une meilleure compréhension des raisons de cette non-compliance aiderait à mieux identifier les patientes à risque et à développer des interventions capables d'améliorer l'adhésion à l'hormonothérapie adjuvante.C'est dans ce but que nous avons entrepris une revue de la littérature des six dernières années (Pub Med 2003-2006).
Howell A, Cuzick J, Baum L, et al. - Results of the ATAC (arimidex, tamoxifen, alone or in combination) trial after completion of 5 years'adjuvant treatment for breast cancer. Lancet, 2005, 365, 60-62. (Pubitemid 40082147)
Coombes RC, Kilburn LS, Snowdon CF, et al. - Survival and safety of examestane versus tamoxifen after 2-3 years'tamoxifen treatment (Intergroup Examestane Study) : a randomised controlled trial. Lancet, 2007, 369, 559-570.
Partridge AH, La Fountain A, Mayer E, et al. - Adherence to Initial Adjuvant Anastrozole Therapy among Women with Early-Stage Breast Cancer. J Clin Oncol, 2008, 26, 556-562.
Partridge AH, Wang PS, Winer EP, et al. - Non-adherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol, 2003, 21, 602-606. (Pubitemid 46621892)
Observance d'un traitement de longue durée : un grand défi pour le médecin et la patiente. Mutualités Libres, Septembre 2008.
Coombes RC, Hall E, Gibson LJ, et al. - Intergroup Examestane Study: a randomized trial of examestane after 2 to 3 years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med, 2004, 350, 1081-1092. (Pubitemid 38298988)
Goss PE, Ingle JL, Martino S, et al. - A randomised trial of letrozol in postmenopausal women after 5 years of tamoxifen therapy for early-stage breast cancer. N Engl J Med, 2003, 349, 1793-1802.
Osterberg L, Blaschke T. - Adherence to medication. N Engl J Med, 2005, 353, 487-497.
Van Dulmen S, Sluijs E, van Dijk L, et al. - Patient adherence to medical treatment : a review of reviews. BMC Health Services Research, 2007, 7, 55-58. (Pubitemid 46668110)
Alliotta SL, Vlasnik JJ, Delor B. - Enhancing adherence to long-term medical therapy, a new approach to assessing and treating patients. Adv Therapy, 2004, 21, 214-231.
Chlebowski RT, Geller ML. - Adherence to endocrine therapy for breast cancer. Oncology, 2006, 71, 1-9.
Kahn KL, Schneider EC, Malin JL et al. - Patient-centred experiences in breast cancer. Predicting long-term adherence to tamoxifen use. Med Care, 2007, 45, 431-439.
Owusu C, Buist DS, Field TS, et al. - Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer. J Clin Oncol, 2008, 26, 549-555.
Kimmick G, Anderson R, Camacho F, et al. - Adjuvant hormonal therapy use among insured, low-income women with breast cancer. J Clin Oncol, 2009, 27, 3445-3451.
Kripalini S, Yao X, Haynes RB. - Intervention to enhance medication adherence in chronic medical conditions. Arch Intern Med, 2007, 167, 540-550.
Krousel-Wood W, Hyre A, Muntner P, et al. - Methods to improve medication adherence in patients with hypertension : current status and future directions. Cur Opin Cardiol, 2005, 20, 296-300. (Pubitemid 40896368)
Neven P, Markopoulos C, Tanner L, et al. - The CARIATIDE Study : evaluation of the impact of educational material on the compliance and persistence rates to adjuvant aromatase inhibitor medication in postmenopausal breast cancer patients. ECCO 15-34th ESMO Multidisciplinary Congress 20-24 September 2009, Berlin, Germany. Abstract id. 5.134.
